Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

How much is that cure in the window? Pharma testing the wate...

Melissa Hogan, mother of a patient with a rare disease, explores the possibility of pharma developing cures for rare diseases. No one's ever asked me to run in a "Race for the Treatment." It certainly doesn't sound as motivating as a Race for the Cure…

Articles

Being diagnosed with cryoglobulinemia

Diane Dike, Ph.D. shares her experience in being diagnosed with a rare disease and discusses the importance of online patient communities when it comes to dealing with a diagnosis. It can be lonely, scared and confusing being a patient diagnosed with a rare disease. In Europe, a disease is considered rare when...

Articles

Pharma news highlights: lawsuits and recalls

Ed Silverman discusses the latest pharma developments, from lawsuits to recalls, in his last piece before the New Year. The end of the year must be near, because a batch of interesting developments has occurred over the past...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital